Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;24(2):105-122.
doi: 10.1038/s41568-023-00650-x. Epub 2024 Jan 9.

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

Melody Riaud #  1   2 , Jennifer Maxwell #  2   3 , Isabel Soria-Bretones #  1   2   4 , Matthew Dankner  2   5   6 , Meredith Li  1 , April A N Rose  7   8   9
Affiliations
Review

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies

Melody Riaud et al. Nat Rev Cancer. 2024 Feb.

Abstract

The RAF family of kinases includes key activators of the pro-tumourigenic mitogen-activated protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF, drives tumour progression and drug resistance in many types of cancer. Although BRAF is the most studied RAF protein, partially owing to its high mutation incidence in melanoma, the role of CRAF in tumourigenesis and drug resistance is becoming increasingly clinically relevant. Here, we summarize the main known regulatory mechanisms and gene alterations that contribute to CRAF activity, highlighting the different oncogenic roles of CRAF, and categorize RAF1 (CRAF) mutations according to the effect on kinase activity. Additionally, we emphasize the effect that CRAF alterations may have on drug resistance and how precision therapies could effectively target CRAF-dependent tumours. Here, we discuss preclinical and clinical findings that may lead to improved treatments for all types of oncogenic RAF1 alterations in cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Santarpia, L., Lippman, S. M. & El-Naggar, A. K. Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy. Expert. Opin. Ther. Targets 16, 103–119 (2012). - PubMed - PMC - DOI
    1. Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291–3310 (2007). - PubMed - DOI
    1. Bollag, G. et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12, 144–148 (1996). - PubMed - DOI
    1. Freeman, A. K., Ritt, D. A. & Morrison, D. K. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 49, 751–758 (2013). - PubMed - PMC - DOI
    1. Kong, T. et al. Role of the extracellular signal-regulated kinase 1/2 signaling pathway in ischemia-reperfusion injury. Front. Physiol. 10, 1038 (2019). - PubMed - PMC - DOI

MeSH terms

Substances

-